On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
For children in hospitals, sometimes the best medicine and moments of joy can come with four paws, a wet nose, and a wagging tail. Today, the Joy in Childhood Foundation, the independent charitable foundation powered by Dunkin’ and Baskin-Robbins, is launching its Dogs for Joy program to bring in-residence dogs to children’s hospitals nationwide. Dogs in this program are bred and trained as service dogs but “work” full-time in children’s hospitals. Through more than $2M in initial grants the program will dramatically increase the number of in-residence dog programs in pediatric healthcare settings around the country and the prevalence of animal-assisted therapy as part of treatment.
To view the multimedia release go to:
https://www.multivu.com/players/English/8444851-joy-in-childhood-foundation-unleashes-dogs-for-joy/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Sally Hansen continues to lead in innovation by introducing its new Color Therapy products: a nail polish, top coat, and nail & cuticle oil, inspired by women’s desire to wear beautiful color while simultaneously caring for their nails. Sally Hansen’s Color Therapy nail polish contains a patented micro-delivery system that delivers an argan oil-enriched formula, resulting in intensive nourishment and instant moisture for healthier-looking nails. The Color Therapy nail polish needs no base coat so the oil complex can directly contact the bare nail. 9 out of 10 women experienced a noticeable improvement in their natural nails after wearing the Color Therapy nail polish. Vibrant tones, available in three magnificent palettes, glide on for a radiant, shiny finish with up to 10 days of fade-proof, chip-resistant wear. The Color Therapy nail polish provides the ultimate color that cares while you wear, with everything needed to restore nails without sacrificing luminous color.
Complete your manicure with the Color Therapy top coat and nail & cuticle oil, both formulated with the same argan oil contained in the nail polish. The top coat provides an ultra-glossy finish for extended wear, and the nail & cuticle oil, the ultimate in nail therapy, instantly makes nails and cuticles look healthier, restored, and rejuvenated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7957151-sally-hansen-color-therapy-nail-polish/
The face – and hair – of CLEAR SCALP & HAIR BEAUTY THERAPY™, Heidi Klum, rallied women at The Grove in Los Angeles, and across America, and invited them to join her and work at the right end of hair – the scalp. For years, women have been working at the ends of hair, rather than the foundation. Ninety-nine percent of hair’s natural strength and beauty comes from the scalp; CLEAR SCALP & HAIR BEAUTY THERAPY™ nourishes the scalp and creates the right foundation for strong, beautiful hair from root to tip. In an effort to spread the message of working at the right end of hair, CLEAR SCALP & HAIR BEAUTY THERAPY™ is calling attention to the “Right End” Hair Revolution – a movement that began last spring and is inspiring women to adopt a haircare regimen that starts with scalp nourishment.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61517-heidi-klum-clear-scalp-and-hair-beauty-therapy-right-end-hair-revolution
http://acne.gd/clear-remedy/
I am glad I was in a position to attempt this item with a reduced cost, because frankly it did not reside up to its billing. The therapy system is according to salicylic acid and other
This is a testimony from a couple that went through our Marriage Intensive program. Our team of marriage counselors consists of Psychologists, Marriage/Family Therapists, and Licensed Counselors. saving marriages through intensives. Marriage Help for you.
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
